Vaginal films
View Patent ↗Provided herein are stable, dissolvable films containing active ingredients, such as antimicrobial composition, antiviral compositions, or anti-retroviral compositions for intravaginal or intrarectal placement to provide prophylaxis against viral infections.
1. A dissolvable film comprising 6% wt. hydroxyethyl cellulose, 6% wt. hydroxypropyl methyl cellulose, and 2% carboxymethyl cellulose, a plasticizer, and 2% wt. of a nucleoside reverse transcriptase inhibitor.
2. The dissolvable film of claim 1 , wherein the nucleoside reverse transcriptase inhibitor comprises tenofovir or a pharmaceutically-acceptable salt thereof.
3. The dissolvable film of claim 2 , further comprising dipivefrine or a pharmaceutically-acceptable salt thereof.
4. The dissolvable film of claim 1 , wherein the carboxymethyl cellulose is sodium carboxymethyl cellulose.
5. The dissolvable film of claim 1 , wherein the plasticizer comprises 2% wt. glycerin.
6. This dissolvable film of claim 1 , wherein the nucleoside reverse transcriptase inhibitor is tenofovir.
7. The dissolvable film of claim 6 , wherein the tenofovir is tenofovir disoproxil.
8. The dissolvable film of claim 6 , wherein the film further comprises dapivirine.
9. The dissolvable film of claim 1 , wherein the film further comprises 0.28% wt. sodium hydroxide.
10. A dissolvable film formed from an aqueous solution comprising 6% wt. hydroxyethyl cellulose, 6% wt. hydroxypropyl methyl cellulose, 2% wt. carboxymethyl cellulose, 2% wt. glycerin, and 2% wt. tenofovir.
11. The dissolvable film of claim 5 , wherein the film comprises 6% wt. hydroxyethyl cellulose, 6% wt. hydroxypropyl methyl cellulose, 2% wt. carboxymethyl cellulose, 2% wt. glycerin, and 2% wt. tenofovir, and further comprises 0.28% wt. sodium hydroxide.